8.75
Regenxbio Inc stock is traded at $8.75, with a volume of 890.91K.
It is up +4.04% in the last 24 hours and up +6.58% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$8.41
Open:
$8.7
24h Volume:
890.91K
Relative Volume:
0.92
Market Cap:
$440.90M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.6635
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-3.74%
1M Performance:
+6.58%
6M Performance:
+10.76%
1Y Performance:
-38.77%
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RGNX
Regenxbio Inc
|
8.75 | 442.92M | 89.04M | -241.08M | -194.72M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
598.89 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.94 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
Feb-07-25 | Resumed | Raymond James | Outperform |
Nov-15-24 | Resumed | Morgan Stanley | Overweight |
Oct-10-24 | Resumed | Raymond James | Outperform |
Jun-07-24 | Initiated | Goldman | Buy |
Mar-11-24 | Initiated | H.C. Wainwright | Buy |
Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Feb-21-24 | Resumed | Raymond James | Outperform |
Nov-01-23 | Initiated | Stifel | Buy |
Jun-02-23 | Initiated | Robert W. Baird | Outperform |
Jun-23-22 | Initiated | Berenberg | Buy |
Dec-15-21 | Initiated | Wedbush | Neutral |
Oct-19-21 | Resumed | Morgan Stanley | Overweight |
Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
Dec-16-20 | Initiated | UBS | Buy |
Jun-25-20 | Resumed | BofA/Merrill | Buy |
May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
Jun-14-19 | Resumed | Raymond James | Outperform |
Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
May-09-18 | Reiterated | Barclays | Overweight |
Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
Feb-13-18 | Initiated | Mizuho | Neutral |
Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
REGENXBIO Inc. Reaches Critical Trendline SupportLow Capital High Return Stock Plans Reviewed - metal.it
REGENXBIO Inc. Inches Above Key Support — Safe to HoldTarget Return Focused Trade Insights Shared - metal.it
How many analysts rate REGENXBIO Inc. as a “Buy”AI Powered Tips For 2025 - jammulinksnews.com
Duchenne Muscular Dystrophy Market to Witness Significant Expansion During the Forecast Period (2025–2034) Amidst Advances in Gene Therapy and Novel Drug Approvals | DelveInsight - GlobeNewswire Inc.
What are the latest earnings results for REGENXBIO Inc.Get daily updates on promising stocks - jammulinksnews.com
What is the dividend policy of REGENXBIO Inc. stockRobust investment performance - jammulinksnews.com
What catalysts could drive REGENXBIO Inc. stock higher in 2025Maximize your portfolio’s earning power - jammulinksnews.com
What makes REGENXBIO Inc. stock price move sharplyBuild a portfolio that stands the test of time - jammulinksnews.com
What drives REGENXBIO Inc. stock priceJaw-dropping returns - PrintWeekIndia
What institutions are buying REGENXBIO Inc. stock nowTriple returns potential - jammulinksnews.com
REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey
What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional
The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com
REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com
REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance
(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News
Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com
RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
Duchenne gene therapy interim trial outcomes "striking" - MarketScreener
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mills Kenneth T. | Director |
May 12 '25 |
Sale |
7.91 |
20,602 |
163,046 |
475,103 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):